GlassScriptPhysician profile
Denise Hays Devine
NPI 1801855614
$2,034.27
in general payments reported to CMS, 2019-2025
29 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $158 · 2021: $253 · 2022: $341 · 2023: $294 · 2024: $336 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.95 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $180.92 | 2019-2024 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Channel Medsystems, INC. | $177.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.87 | 2019-2025 | |
| Exeltis, USA INC. | $131.27 | 2020-2025 | Slynd |
| Minerva Surgical, INC | $101.00 | 2023-2025 | |
| Therapeuticsmd, INC. | $93.39 | 2019-2022 | |
| Sage Therapeutics, LLC | $87.03 | 2021-2025 | Zurzuvae |
| Optumhealth Care Solutions, LLC | $80.39 | 2023-2025 | Eitan Medical, Vivify Health Care Team Portal 001, Vivify Health Care Team Portal |
| Evofem Biosciences, INC. | $74.08 | 2021-2023 | Phexxi |
| Allergan, INC. | $65.51 | 2019 | |
| Shield Therapeutics INC | $61.27 | 2024-2025 | |
| Astellas Pharma US INC | $48.72 | 2024 | Veozah |
| Organon LLC | $40.74 | 2024-2025 | Nexplanon |
| Pfizer INC. | $39.24 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $38.73 | 2019-2020 | |
| Lupin INC. | $36.90 | 2019 | |
| Merck Sharp & Dohme LLC | $36.60 | 2019-2023 | Gardasil 9 |
| Mayne Pharma Commercial LLC | $33.58 | 2021-2025 | |
| Dexcom, INC. | $29.05 | 2024 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $26.13 | 2021-2024 | Twirla |
| Amag Pharmaceuticals, INC. | $26.13 | 2019-2020 | |
| Coopersurgical, INC. | $21.81 | 2025 | Paragard T 380a |
| Duchesnay USA Incorporated | $21.10 | 2019 | |
| Amgen INC. | $17.95 | 2019 | |
| Smith+Nephew, INC. | $15.78 | 2024 | Pico |
| Daiichi Sankyo INC. | $14.65 | 2019 | |
| Avion Pharmaceuticals | $13.26 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.